Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 23 Results

Intervention Indication Therapeutic Area Year Actions
Spartalizumab in addition to dabrafenib and trametinib for unresectable or metastatic BRAF V600 mutant melanoma – first‐line Dabrafenib (Tafinlar; GSK2118436; dabrafenib mesilate) , Spartalizumab (PDR001) , Trametinib (Mekinist; TMT212; GSK-1120212B; GSK1120212; JTP-74057; trametinib dimethyl sulfoxide) Melanoma Skin Cancer 2019 View  |  Download
Talimogene laherparepvec in addition to pembrolizumab for metastatic melanoma Pembrolizumab (Keytruda; MK-3475) , Talimogene laherparepvec (Imlygic; T-Vec) Melanoma Skin Cancer 2020 View  |  Download
Vemurafenib (Zelboraf) for BRAF V600 mutation positive melanoma; completely resected but at high risk of recurrence Vemurafenib (Zelboraf; PLX4032; R7204; RO5185426; PLX-4032; RG7204) Melanoma Skin Cancer 2017 View  |  Download
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications